Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice

Lignende værker

• Leukopenia is a biomarker for effective temozolomide dosing and predicts overall survival of patients with glioblastoma
  af: Ho, K. Grace, et al.
  Udgivet: (2020)
• Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years
  af: Ohno, Makoto, et al.
  Udgivet: (2019)
• The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide and Irinotecan for Newly Diagnosed Glioblastoma
  af: Vredenburgh, James J., et al.
  Udgivet: (2011)
• Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial
  af: Sandmann, Thomas, et al.
  Udgivet: (2015)
• Similar overall survival with reduced vs. standard dose bevacizumab monotherapy in progressive glioblastoma
  af: Gleeson, Jack Patrick, et al.
  Udgivet: (2019)